Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Piperine, the active alkaloid in black pepper (Piper nigrum), has been studied for its potential benefits in inflammatory bowel disorders (IBD), such as Crohn’s disease and ulcerative colitis. Preclinical research, primarily in animal models, demonstrates that piperine exhibits anti-inflammatory effects. These studies suggest that piperine can suppress the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), and inhibit the activation of nuclear factor-kappa B (NF-κB), a key regulator of inflammation in IBD. Additionally, piperine may reduce oxidative stress and protect intestinal mucosa from inflammatory damage.

However, evidence in humans is currently limited. Few, if any, clinical trials have directly assessed piperine supplementation in patients with IBD. Most data come from animal studies or in vitro experiments. While the mechanistic rationale is strong, and initial results are promising, the lack of robust human evidence means that piperine cannot be considered a proven therapy for IBD at this time. It is sometimes used as an adjunct in combination with other compounds (such as curcumin) to enhance bioavailability, but its standalone effects in human IBD remain uncertain.

In summary, the use of piperine for IBD is supported by preclinical scientific evidence, but current human data are insufficient to recommend it as a primary treatment. Further clinical studies are needed to establish its efficacy and safety in this context.

More about Piperine
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Piperine

Products containing Piperine